https://doi.org/10.4081/monaldi.2023.2778

PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients

Early Access
Submitted: September 12, 2023
Accepted: October 19, 2023
Published: November 3, 2023
Lung carcinoma; molecular profile; EGFR; PD-L1
Abstract Views: 598
PDF_early view: 433
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Yoldez Houcine
https://orcid.org/0000-0002-7155-5519
Pathology Department, Salah Azaiz Institute, Tunis; Faculty of Medicine of Tunis, El Manar University, Tunis, Tunisia.
Chirine Moussa
chirine.moussa@fmt.utm.tn
https://orcid.org/0000-0002-8123-9843
Faculty of Medicine of Tunis, El Manar University, Tunis; Pneumology Department 1, Abderrahmen Mami Hospital, Ariana, Tunisia.
Ahmed Ben Abdelaziz
Epidemiology and Statistics Department, Farhat Hached Hospital, Sousse, Tunisia.
Aida Ayadi
Faculty of Medicine of Tunis, El Manar University, Tunis; Pathology Department, Abderrahmen Mami Hospital, Ariana, Tunisia.

In cancer treatment, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are thriving. Activated T lymphocytes expressed PD-1, it works with its ligand PD-L1 to limit T lymphocyte activation and prevent autoimmune disease. The expression of molecular biomarkers and PD-L1 in lung cancer determines the appropriate treatment strategy for patients with lung cancer. The purpose of this study was to look at the prevalence of molecular biomarkers and PD-L1 expression in a large group of Tunisian patients with advanced non-small cell lung cancer. We conducted an observational retrospective study in which medical/treatment history data were extracted retrospectively from medical records and archived tissue samples between January 1st 2019 and December 31st 2021. We gathered 157 patients who had recently been diagnosed with non-small cell lung carcinoma. In 36.9%of the cases, there was no molecular genotyping. EGFR (28.6%), KRAS (5.73%), and ALK gene rearrangement were the most common genotyping mutations (3.8%). ROS1 rearrangement was not present. There was a link between EGFR and gender, HER and age, and KRAS and biopsy tissue origin. Six of the tested cases with PD-L1 met the cut-off (³50%). PD-L1 positivity was more common in solid type adenocarcinoma (1.9%) than in acinar or papillary adenocarcinoma. There were no significant differences in PD-L1 expression across clinical and demographic parameters. High PD-L1 expression and molecular abnormalities were found in 1 case of EGFR, 1 case of BRAF, and 1 case of KRAS (3 cases). All of the other specimens with abnormalities had a PD-L1 <50%. ALK, ROS1, BRAF, KRAS, and MET were found to be significantly associated with PD-L1 expression. Our study is one of the country's largest, describing a large panel of biomarkers and their clinicopathologic/histopathologic associations in Tunisian lung cancer patients. We have the same molecular profile as European patients with an EGFR mutation, which is not the most common genotype abnormality in Tunisian patients. There is only one mutation at any given time. The expression of PD-L1 is determined by the histologic type and the origin of the biopsy tissue.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388;1459-544.
Bray F, Ferlay J, Soerjomataram I, et al. A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI: https://doi.org/10.3322/caac.21492
Cherif A, Dhaouadi S , Osman M, Hsairi M. Breast Cancer burden in Tunisia: situation in 2017 and projections by 2030. Eur J Public Health 2019;29:ckz186.232. DOI: https://doi.org/10.1093/eurpub/ckz186.232
World Health Organization. WHO classification of thoracic tumours, 5th Edition, Volume 5. World Health Organization, Geneva.
Zugazagoitia J, Enguita AB, Nuñez JA, et al. The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis 2014;6:S526-36.
Petersen I, Warth A. Lung cancer: developments, concepts, and specific aspects of the new WHO classification. J Cancer Res Clin Oncol 2016;142:895-904. DOI: https://doi.org/10.1007/s00432-015-2004-4
Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol 2018;13:301-22. DOI: https://doi.org/10.1016/j.jtho.2018.01.002
Soo RA, Stone ECA, Cummings KM, et al. Scientific advances in thoracic oncology 2016. J Thorac Oncol 2017;12:1183-209. DOI: https://doi.org/10.1016/j.jtho.2017.05.019
Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J Thorac Oncol 2020;15:499-519. DOI: https://doi.org/10.1016/j.jtho.2019.12.107
LindemanNl, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018;142:321-46. DOI: https://doi.org/10.5858/arpa.2017-0388-CP
Girard N. [Les algorithmes de prise en charge des cancers bronchiques avancés et métastatiques en 2020: traitements de 1re intention].[Article in French]. Corresp Onco-Theran 2020;1:49-45.
Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012;10:1236-1271. DOI: https://doi.org/10.6004/jnccn.2012.0130
Alexander M, Kim SY, Cheng H. Update 2020: Management of non-small cell lung cancer. Lung 2020;198:897-907. DOI: https://doi.org/10.1007/s00408-020-00407-5
Mohan A, Garg A, Gupta A, et al. Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020;37:190-7. DOI: https://doi.org/10.4103/lungindia.lungindia_333_19
Rahman S, Kondo N, Yoneda K, et al. Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. Int J Clin Oncol 2014;19:45-9. DOI: https://doi.org/10.1007/s10147-012-0515-4
Rana V, Ranjan P, Jagani R, et al. A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study. Med J Armed Forces India 2018;74:148-53. DOI: https://doi.org/10.1016/j.mjafi.2017.09.005
O’Leary C, Andelkovic V, Ladwa R, et al. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 2019;8:1119-24. DOI: https://doi.org/10.21037/tlcr.2019.10.22
Westeel V, Ranchon F, Toffart AC, et al. [Référentiel sur le cancer bronchique non à petites-cellules: actualisation 2021].[in French]. ARISTOT; Paris: 2021.
Gupta P, Saha K, Vinarkar S, et al. Next generation sequencing in lung cancer: An initial experience from India. Curr Probl Cancer 2020;44:100562. DOI: https://doi.org/10.1016/j.currproblcancer.2020.100562
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. DOI: https://doi.org/10.1056/NEJMoa1606774
Huang RSP, Haberberger J, Severson E, et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol 2021;34:252-63. DOI: https://doi.org/10.1038/s41379-020-00664-y
Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 2020;13:17-33. DOI: https://doi.org/10.1016/j.path.2019.11.002
Song P, Wu S, Zhang L, et al. Correlation between PD-L1 expression and clinicopathologic features in 404 patients with lung adenocarcinoma. Interdiscip Sci Comput Life Sci 2019;11;258-65 . DOI: https://doi.org/10.1007/s12539-019-00329-8
Koh J, Go H, Keam B et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28:1154-66. DOI: https://doi.org/10.1038/modpathol.2015.63
Zhang Y, Wang L, Li Y et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-73. DOI: https://doi.org/10.2147/OTT.S59959
Heymann JJ, Bulman WA, Swinarski D, et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol 2017;125:896-907. DOI: https://doi.org/10.1002/cncy.21937
Rossi E, Aieta M, Tartarone A, et a . A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res 2021;10:80-92. DOI: https://doi.org/10.21037/tlcr-20-855
Lei Y, Xu Y, Li S, et al. Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thorac Cancer 2023;14: 2327-37. DOI: https://doi.org/10.1111/1759-7714.15021

How to Cite

Houcine, Yoldez, Chirine Moussa, Ahmed Ben Abdelaziz, and Aida Ayadi. 2023. “PDL1 and Molecular Biomarkers Expression in Non-Small Cell Lung Cancer in Tunisian Patients”. Monaldi Archives for Chest Disease, November. https://doi.org/10.4081/monaldi.2023.2778.
Copyright (c) 2023 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.